-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, LeJPZmfkdzoVE64qpMsfM5WuHRWDk+8KTUXHYVpqN+a2f98fcxIw0LDvJ8PwzYQw UV1lNQsCedrU8Ld6gcDYsA== 0001144204-08-063450.txt : 20081113 0001144204-08-063450.hdr.sgml : 20081113 20081113163817 ACCESSION NUMBER: 0001144204-08-063450 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20080725 FILED AS OF DATE: 20081113 DATE AS OF CHANGE: 20081113 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: NEUROGEN CORP CENTRAL INDEX KEY: 0000849043 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 222845714 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 35 NORTHEAST INDUSTRIAL RD CITY: BRANFORD STATE: CT ZIP: 06405 BUSINESS PHONE: 2034888201 MAIL ADDRESS: STREET 1: 35 NORTHEAST INDUSTRIAL RD CITY: BRANFORD STATE: CT ZIP: 06405 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: BAKER FELIX CENTRAL INDEX KEY: 0001087940 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-18311 FILM NUMBER: 081185449 BUSINESS ADDRESS: STREET 1: TISCH FAMILY INTERESTS STREET 2: 667 MADISON AVENUE CITY: NEW YORK STATE: NY ZIP: 10021 BUSINESS PHONE: 212-339-5600 MAIL ADDRESS: STREET 1: BAKER BROTHERS ADVISORS STREET 2: 667 MADISON AVENUE CITY: NEW YORK STATE: NY ZIP: 10021 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: BAKER JULIAN CENTRAL INDEX KEY: 0001087939 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-18311 FILM NUMBER: 081185450 BUSINESS ADDRESS: STREET 1: TISCH FAMILY INTERESTS STREET 2: 667 MADISON AVENUE CITY: NEW YORK STATE: NY ZIP: 10021 BUSINESS PHONE: 212-339-5600 MAIL ADDRESS: STREET 1: BAKER BROTHERS ADVISORS STREET 2: 667 MADISON AVENUE CITY: NEW YORK STATE: NY ZIP: 10021 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Baker Biotech Capital (GP), LLC CENTRAL INDEX KEY: 0001244389 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-18311 FILM NUMBER: 081185451 BUSINESS ADDRESS: STREET 1: 667 MADISON AVE 17TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10065 BUSINESS PHONE: 212-339-5600 MAIL ADDRESS: STREET 1: 667 MADISON AVE 17TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10065 FORMER NAME: FORMER CONFORMED NAME: BAKER BIOTECH CAPITAL GP LLC DATE OF NAME CHANGE: 20030619 4 1 form418389_111308163755-.xml X0303 4 2008-07-25 0 0000849043 NEUROGEN CORP NRGN 0001244389 Baker Biotech Capital (GP), LLC 667 MADISON AVENUE, 17TH FLOOR NEW YORK NY US 10021 1 0 1 0 0001087939 BAKER JULIAN 667 MADISON AVENUE, 17TH FLOOR NEW YORK NY US 10021 1 0 1 0 0001087940 BAKER FELIX 667 MADISON AVENUE, 17TH FLOOR NEW YORK NY US 10021 1 0 1 0 Common Stock 2008-07-25 4 C 0 1304550 A 3500059 I Through Partnership Series A Convertible Preferred Stock 2008-07-25 4 C 0 50175 0 D Common Stock 1304550 0 I Through Partnership In addition to Baker Biotech Capital (GP), LLC, this Form 4 is being filed jointly by Julian C. Baker and Felix J. Baker, each of whom has the same business address as Baker Biotech Capital (GP), LLC and may be deemed to have a pecuniary interest in securities owned by it. Julian C. Baker and Felix J. Baker are Directors of the Issuer. Because of certain relationships with other security holders of the Issuer, the Reporting Persons are filing solely for informational purposes as if they were members of a group of such shareholders. (Continued in footnote 2). However, the Reporting Persons disclaim that they and any other person or persons, in fact constitute a "group" for purposes of Section 13(d)(3) of the Securities Exchange Act of 1934, as amended, or Rule 13d-5 thereunder or that they are the beneficial owners of securities owned by any such other persons, and each of them disclaims beneficial ownership of securities reported herein except to the extent of their pecuniary interest, if any, therein. Each share of Preferred Stock was automatically converted to 26 shares of common stock upon the approval of the stockholders of the Issuer. Additionally, upon such approval the 50,175 warrants issued on April 11, 2008 became exercisable at an exercise price of $2.30 per share. The warrants expire on April 11, 2013. Represents securities owned directly by 667, L.P. (formerly Baker Biotech Fund I, L.P.), the sole general partner of which is Baker Biotech Capital, L.P., a limited partnership the sole general partner of which is Baker Biotech Capital (GP),LLC. Julian C. Baker and Felix J. Baker are the controlling members of Baker Biotech Capital (GP), LLC. /s/ Julian C. Baker, as Managing Member of Baker Biotech Capital (GP), LLC 2008-11-13 /s/ Julian C. Baker 2008-11-13 /s/ Felix J. Baker 2008-11-13 -----END PRIVACY-ENHANCED MESSAGE-----